Development of a consensus-based delineation guideline for locally recurrent rectal cancer

Piqeur, F.; Hupkens, B.J.P.; Nordkamp, S.; Witte, M.G.; Meijnen, P.; Ceha, H.M.; ... ; Peulen, H.M.U.

Radiotherapy and Oncology 177 (2022) 214–221

Contents lists available at ScienceDirect

Radiotherapy and Oncology

journal homepage: www.thegreenjournal.com

Original Article

Development of a consensus-based delineation guideline for locally recurrent rectal cancer

Floor Piqeur [a,b,c,1], Britt J.P. Hupkens [a,d,1], Stefi Nordkamp [e], Marnix G. Witte [b], Philip Meijnen [f], Heleen M. Ceha [g], Maaike Berbee [d], Margriet Dieters [h], Sofia Heyman [i], Alexander Valdman [j], Martin P. Nilsson [k], Joost Nederend [l], Harm J.T. Rutten [e,m], Jacobus W.A. Burger [e], Corrie A.M. Marijnen [b,c], Heike M.U. Peulen [a,*]

[a] Department of Radiation Oncology, Catharina Hospital, Michelangelolaan 2, 5623EJ Eindhoven; [b] Department of Radiation Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam; [c] Department of Radiation Oncology, Leiden University Medical Centre, Albinusdreef 2, 2333ZA Leiden; [d] Department of Radiation Oncology (Maastro), GROW School for Oncology and Reproduction, Maastricht University Medical Centre+, Doctor Tanslaan 12, 6229ET Maastricht; [e] Department of Surgery, Catharina Hospital, Michelangelolaan 2, 5623EJ Eindhoven; [f] Department of Radiation Oncology, Amsterdam University Medical Centre, De Boelelaan 1118, 1081HZ Amsterdam; [g] Department of Radiation Oncology, Haaglanden Medical Centre, Burg. Banninglaan 1, 2262AK Leidschendam; [h] Department of Radiation Oncology, University Medical Centre Groningen, Hanzeplein 1, 9713GZ Groningen, the Netherlands; [i] Department of Oncology, Institute of Clinical Sciencs, Sahlgrenska Academy at University of Gothenburg, Bla straket 5, 412 45 Götenborg; [j] Department of Radiation Oncology, Karolinska University Hospital, Anna Stecksén gata 41, 171 64 Stockholm; [k] Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lasarettsgatan 23, 221 85 Lund, Sweden; [l] Department of Radiology, Catharina Hospital, Michelangelolaan 2, 5623 EJ Eindhoven; and [m] GROW School of Oncology and Developmental Biology, University of Maastricht, Universiteitssingel 40, 6229ER Maastricht, the Netherlands

ARTICLE INFO

Article history:
Received 5 July 2022
Received in revised form 8 November 2022
Accepted 13 November 2022
Available online 21 November 2022

Keywords:
Locally recurrent rectal cancer
Delineation guideline
Inter-observer variation
Consensus-based
Re-irradiation
Multidisciplinary target volume definition

ABSTRACT

Background and purpose: Neoadjuvant chemoradiotherapy (nCRT) is used in locally recurrent rectal cancer (LRRC) to increase chances of a radical surgical resection. Delineation in LRRC is hampered by complex disease presentation and limited clinical exposure. Within the PelvEx II trial, evaluating the benefit of chemotherapy preceding nCRT for LRRC, a delineation guideline was developed by an expert LRRC team.
Materials and methods: Eight radiation oncologists, from Dutch and Swedish expert centres, participated in two meetings, delineating GTV and CTV in six cases. Regions at-risk for re-recurrence or irradical resection were identified by eleven expert surgeons and one expert radiologist. Target volumes were evaluated multidisciplinary. Inter-observer variation was analysed.
Results: Inter-observer variation in delineation of LRRC appeared large. Multidisciplinary evaluation per case is beneficial in determining target volumes. The following consensus regarding target volumes was reached. *GTV* should encompass all tumour, including extension into OAR if applicable. If the tumour is in fibrosis, GTV should encompass the entire fibrotic area. Only if tumour can clearly be distinguished from fibrosis, GTV may be reduced, as long as the entire fibrotic area is covered by the CTV. *CTV* is GTV with a 1 cm margin and should encompass all at-risk regions for irradical resection or re-recurrence. CTV should not be adjusted towards other organs. Multifocal recurrences should be encompassed in one CTV. Elective nodal delineation is only advised in radiotherapy-naïve patients.
Conclusion: This study provides a first consensus-based delineation guideline for LRRC. Analyses of re-recurrences is needed to understand disease behaviour and to optimize delineation guidelines accordingly.

 Radiotherapy and Oncology 177 (2022) 214–221

In the past decades, treatment outcome of locally recurrent rectal cancer (LRRC) has improved significantly.[1–5] Intensification of neoadjuvant treatment for LRRC is used to improve oncologic outcome. [1,2,6,7] Currently, neoadjuvant chemoradiotherapy (nCRT) is an integral part of LRRC treatment.[2,8–16] In radiotherapy naïve patients, nCRT is advised to downstage tumour volume and increase the likelihood of a radical resection (R0), which is the most important prognostic factor for survival.[1,4] Re-irradiation in the setting of LRRC is feasible and safe, confirmed by low toxicity rates seen in the first prospective re-irradiation feasibility trial for LRRC performed by Valentini et al.[17] Although re-

Abbreviations: LRRC, Locally recurrent rectal cancer; GTV, Gross tumour volume; CTV, Clinical target volume; PTV, Planning target volume; nCRT, Neoadjuvant chemoradiotherapy; OAR, Organs at risk; R0, Radical resection; OS, Overall survival; RCT, Randomized controlled trial; DSC, Dice similarity coefficient; HD, Hausdorff distance; QA, Quality Assurance.

[1] Both authors contributed equally.

E-mail address: heike.peulen@catharinaziekenhuis.nl (H.M.U. Peulen)

https://doi.org/10.1016/j.radonc.2022.11.008
0167-8140/

irradiation does show encouraging results, the clinical benefit of re-irradiation is yet to be proven, as nCRT has not yet shown an effect on OS.[2,8,10–14,18] Two ongoing randomized controlled trials (RCT) are investigating the role of neoadjuvant treatment for LRRC. The PelvEx II trial is investigating the benefit of chemotherapy preceding nCRT, hypothesising that additional preoperative chemotherapy will lead to more R0 resections.[19,20] The GRECCAR 15 trial is investigating the benefit of re-irradiation after induction chemotherapy and will also assess percentage of R0 resections as primary endpoint.[20].

Although the use of full course nCRT is promising and the role of re-irradiation for LRRC is being studied, there is no consensus on target volume definition for LRRC. Delineation is hampered as diagnostic imaging is more difficult to interpret due to altered anatomy after primary surgery, multifocality of disease, invasion of surrounding structures, and the presence of fibrosis. Supporting evidence is also lacking. Additionally, clinicians often have limited exposure to LRRC due to the low incidence of disease, as only 6–10 % of patients with rectal cancer develop a local recurrence. [1,2,21]These factors could contribute to inadequate target volume delineation with possible geographical miss. Furthermore, a large inter-observer variability in target volume delineation can be expected.

In primary rectal cancer, a delineation guideline of Valentini et al. has been widely adopted and has proven to reduce inter-observer variability.[22,23] However, to our knowledge, no delineation guidelines have been drawn up for LRRC.

The aim of this study is to develop a consensus-based delineation guideline for LRRC by multidisciplinary delineation workshops in order to decrease delineation variability, to optimize radiotherapy treatment consistency within the PelvEx II trial and to provide radiation oncologists with a guideline for clinical practice.[24].

Materials and methods

All Dutch expert LRRC treatment centres were invited to participate in this study. Expert centres were defined as centres with a dedicated LRRC multidisciplinary tumour board, treating at least 10 patients per year. One radiation oncologist of every Dutch expert centre was asked to delineate three cases of LRRC (cases 1.1–1.3). Dutch participants were instructed to delineate gross tumour volume (GTV), and clinical tumour volume (CTV) according to their own discretion or local guidelines. No margins were specified. Participants received information on patient history, prior treatment, tumour characteristics and imaging for each case. Cases were selected to represent diverse disease presentations, but all cases met PelvEx II inclusion criteria, meaning all patients had confirmed LRRC after mesorectal resection, deemed resectable by the treating surgeon. Tumours invading in the neuroforamina or in the cortex of S2 and upwards and tumours encasing the ischiadic nerve are considered irresectable.[25] Table 1 shows a summary of case characteristics. Case information is presented in the supplementary material (S1).

All delineations were reviewed and discussed multidisciplinarily, with radiation oncologists, surgeons and a radiologist. The participating radiologist and surgeons were asked to identify tumour and regions at risk for re-recurrence or involved resection margins. Following the first meeting, the delineation guideline was drafted. All Dutch radiation oncologists received the concept guideline to review before the second meeting. They were asked to delineate three more cases (cases 2.1–2.3), including one repeat (case 2.1 was a repeat of case 1.2) to test guideline adherence. During the second meeting, the guideline was adjusted based on the discussion. Following the second meeting, the guideline was approved by all participants.



Fig. 1. Consensus delineation for case 1.2 (and 2.1). A: MRI imaging of local recurrence. B: PET imaging of local recurrence, surgical at-risk regions (i.e., sacrospinal ligament) highlighted by white arrows. C: GTV delineation (complete fibrosis). D: CTV delineation (GTV + 1 cm, expanded to encompass at-risk surgical region).

Table 1
Summary of case characteristics, representing diverse disease presentation in LRRC.

	Meeting	Prior radiotherapy	Radiotherapy naïve	Location [**]	Unifocal	Multifocal
Case 1.1	1	X		Lateral, near the pelvic wall	X	
Case 1.2[*]	1	X		Posterior	X	
Case 1.3	1	X		Axial/central		X
Case 2.1[*]	2	X		Posterior	X	
Case 2.2[*]	2		X	Posterior	X	
Case 2.3	2	X		Lateral, obturator loge	X	

[*] Case 1.2 is repeated as case 2.1 to test guideline adherence. Case 2.2 is derived from the same patient as case 1.2 and 2.1, but case information was altered to represent a radiotherapy naïve patient.
[**] Location[25]: Lateral: involving the bony pelvic sidewall or sidewall structures including the iliac vessels, pelvic ureters, lateral lymph nodes, pelvic autonomic nerve, and sidewall musculature; posterior: involving the sacrum and coccyx; axial/central: not involving anterior, posterior, or lateral pelvic sidewalls.

Table 2
Median, minimum and maximum DSC and HD98% of radiation oncologist's GTV and CTV in reference to calculated median GTV and CTV for Dutch participants.

Case#	Case Description		N	DSC			HD 98 % (cm)		
				Median	Min	Max	Median	Min	Max
1.1	**Recurrence near the pelvic wall**	GTV	5	0.76	0.58	0.92	0.84	0.32	1.12
		CTV	5	0.75	0.28	0.86	1.54	0.86	2.87
1.2	**Presacral recurrence**	GTV	5	0.59	0.41	0.81	1.27	0.64	2.26
		CTV	5	0.82	0.27	0.84	2.05	0.98	2.96
1.3	**Multifocal recurrence**	GTV	4	0.57	0.36	0.67	0.75	0.64	1.10
		CTV	4	0.84	0.64	0.94	1.14	0.77	3.20
2.1	**Presacral recurrence, Repeat**	GTV	5	0.66	0.49	0.83	1.22	0.63	1.57
		CTV	5	0.81	0.73	0.87	1.34	1.17	1.85
2.2	**Presacral recurrence, RT naive**	GTV	4	0.66	0.40	0.84	1.20	0.97	1.87
		CTV	4	0.68	0.74	0.90	2.87	0.78	3.54
2.3	**Lateral recurrence**	GTV	4	0.76	0.33	0.83	0.56	0.43	1.21
		CTV	4	0.87	0.35	0.89	0.64	0.55	3.38

Table 3
Median, minimum and maximum DSC and HD98% of radiation oncologist's GTV and CTV in reference to calculated median GTV and CTV for Swedish participants.

Case#	Case Description		N	DSC			HD 98 % (cm)		
				Median	Min	Max	Median	Min	Max
1.1	**Recurrence near the pelvic wall**	GTV	3	0.87	0.63	0.95	0.37	0.15	1.57
		CTV	3	0.89	0.80	0.96	0.63	0.19	1.40
1.2	**Presacral recurrence**	GTV	3	0.80	0.58	0.89	0.83	0.76	2.13
		CTV	3	0.85	0.82	0.94	0.76	0.48	2.03
1.3	**Multifocal recurrence**	GTV	3	0.72	0.11	0.77	0.31	0.13	2.14
		CTV	3	0.90	0.77	0.91	1.68	0.76	2.34
2.1	**Presacral recurrence, Repeat**	GTV	3	0.73	0.72	0.88	0.99	0.71	1.41
		CTV	3	0.87	0.80	0.93	0.85	0.78	1.80
2.2	**Presacral recurrence, RT naive**	GTV	3	0.86	0.70	0.91	0.78	0.43	1.26
		CTV	3	0.87	0.79	0.90	1.58	1.50	4.28
2.3	**Lateral recurrence**	GTV	3	0.64	0.52	0.86	0.57	0.33	0.71
		CTV	3	0.88	0.71	0.91	0.57	0.51	0.98

The delineation study was repeated in Sweden. Radiation oncologists from 3 expert sites were invited to participate and were instructed to delineate according to local practice. No other instructions were provided, however, participants received the Dutch guideline prior to delineation, introducing potential bias. After two meetings with Swedish participants, the final version of the guideline was drafted.

After guideline completion, delineation variation was calculated. The following analyses had no impact on the development of the guideline, but were used to demonstrate delineation variation. Analyses were performed on Dutch and Swedish data separately, to account for potential bias.

Delineations were triangulated into a 3D mesh structure, by use of in-house software (Match42). Median surfaces of contours were constructed to encompass each point designated as target volume by at least 50% of radiation oncologists. Subsequently, analyses were performed in reference to the computed median delineations.

Inter-observer agreement was evaluated using the Dice similarity coefficient (DSC), which is a measure for overlap, for each GTV and CTV in reference to computed median.[26] A DSC of 1.0 signifies a perfect overlap between two delineations, whereas a DSC of 0.0 signifies no overlap.[26].

Distance between median delineation and radiation oncologist's delineation was evaluated using Hausdorff distances (HD).[26] The HD is defined as the maximum of all smallest distances from each point on one delineation to the other. A smaller value of HD corresponds to less variation. The maximum distance, i.e., the HD100%, is sensitive to outliers. Therefore, the HD98% (98th percentile), was used in analysis, to reduce the effect of single outliers.

Comparisons of median DSC and HD98% were performed by Wilxocon sign rank test and Mann-Whitney U test. Statistical analysis was performed using IBM SPSS Statistics for Windows, Version 25.0, IBM Corp. Released 2017. Armonk, NY: IBM Corp.

Results

Six Dutch expert centres (Catharina Hospital Eindhoven, The Netherlands Cancer Institute, Amsterdam University Medical Centre, Maastro, Haaglanden Medical Centre and University Medical Centre Groningen) participated in the Dutch meetings. Delineations were performed by five Dutch radiation oncologists (HP, PM, HC, MB, MD). Four colorectal surgeons (JB, KH, JM, AA) and one radiologist (JN) specialized in colorectal imaging were present.

Three Swedish expert centres (Karolinska Institute, Sahlgrenska University Hospital and Skåne University Hospital) and the Dutch PelvEx II Quality Assurance (QA) team (HP, PB, CM, HR, JN, BH, FP) participated in the Swedish meetings. Other Dutch participants did not attend Swedish meetings. Delineations were performed by three radiation oncologists (SH, AV, MN). Five Swedish colorectal surgeons were present (EA, ML, PN, PB, HI).

Median and range of DSC and HD98% of Dutch and Swedish delineations can be found in Table 2 and Table 3 respectively. Median DSC of GTV for Dutch and Swedish participants ranged from 0.57-0.76 and 0.64–0.87 respectively, suggesting a large variation in GTV contours. The smallest DSC in Dutch contours, i.e., the largest variation, was seen in the multifocal recurrence (case 1.3) (0.57 (0.36–0.67)), and in the recurrence located in fibrosis (case 1.2) (0.59 (0.41–0.81)). Less variation was seen in Swedish contours.

Median DSC of CTV in Dutch and Swedish participants ranged from 0.75-0.87 and 0.87–0.90 respectively. HD98% shows large outliers in Dutch contours, with median HD98% up to 2.05 cm (0.98–2.96) and 2.87 cm (0.78–3.54) in cases 1.2 and 2.2 respectively. Less outliers were seen in Swedish contours (median HD 98 % 0.57 cm-1.68 cm).

When comparing CTV of case 1.2 and 2.1 for Dutch delineations i.e., before and after a guideline, median DSC is equal (0.82 and 0.81 respectively ($p = 0.345$)), but the range suggests a decreasing trend (0.27–0.84 to 0.73–0.87 respectively). The same pattern is seen in median HD98%, with a median HD98% of 2.05 cm (0.98–2.96 cm) in case 1.2 and 1.34 cm (1.1–1.85 cm) in case 2.1 ($p = 0.225$).

Based on defined at-risk regions and consensus delineations, the following guideline was drawn-up. A step-by-step consensus delineation with MRI and FDG-PET is show in Fig. 1. Examples of all consensus delineations are shown in Fig. 2. Performed delineations per case are described in the supplementary material. Table 4 provides a summary of recommendations.

GTV should be determined based on a multidisciplinary consensus with expert radiologists and surgeons. We advise a pelvic MRI, preferably in combination with FDG-PET or CT. All tumour that can be seen at baseline staging must be delineated. This information should be derived from at least diagnostic imaging, supplemented by clinical examination or endoscopic findings. Only involved areas of surrounding organs should be included in the GTV. For example, it is not necessary to encompass the entire bladder at involved levels. In patients receiving induction chemotherapy prior to nCRT, there may be tumour regression. In case of major regression, adjustment towards other structures is allowed. In case of a complete response, there will still be a GTV, i.e., the tumour bed or fibrosis after induction chemotherapy.

If the tumour is located in fibrosis (case 1.2 and 2.1), the entire fibrotic area should be covered by the GTV. Only if distinguishing tumour from fibrosis seems straightforward and highly accurate, GTV may be reduced to encompass only distinguished tumour, as long as the complete fibrotic area is covered by the CTV.

CTV includes all GTV with a margin of 1 cm. In case of chemotherapy preceding nCRT, all pre chemotherapy GTV must be included in the CTV. Given the recurrent nature of the tumour and the loss of anatomical boundaries due to previous surgery, no adjustment of the CTV towards OAR is allowed. The only exception is the pelvic bones, where adjustment of the CTV is allowed if bony invasion is clearly not present, i.e., adjustment of the CTV towards the acetabulum in case of a presacral recurrence. Consequentially, the CTV may extend into the pelvic bones. In case of a multifocal recurrence (case 1.3), all locations should be combined in one CTV, with logical anatomic boundaries. Small separate islands should be avoided. The upper and lower limit are one centimetre beyond the most cranial and caudal GTV.

It is strongly advised to consult with the surgeon to determine at-risk resection margins and surgery type when delineating CTV. Extension of the CTV to encompass all resection margins is strongly advised. Specific attention is needed for adequate coverage of at-risk tissue that will not be surgically removed. If the tumour is located in fibrosis, attention should be payed to sufficient inclusion of the dorsolateral area. No elective nodal delineation is recommended in patients undergoing re-irradiation.

In radiotherapy naïve patients, in contrast to patients undergoing re-irradiation, elective nodal irradiation is advised, mirroring recommendations for primary rectal cancer by Valentini et al [27], with allowance for national adjustments (case 2.2). Anatomical changes due to previous treatment should be considered.

PTV volume ensures coverage of the CTV considering the systematic and random set-up errors, changes over time in the patient geometry and movement of internal organs that may occur. Since the required margin is dependent on local image guidance protocols, the extent of this margin should be determined according to local policy (recommendation between 5 mm and 10 mm).

It is strongly recommended to delineate all OARs, as in primary rectal cancer, i.e., the femoral heads, the bladder, the small bowel, and the anus. Currently, reliable data on OAR constraints are lacking and are highly dependent on the volume and location of the recurrence, thus no optimization objectives can be given yet. The priority should be target coverage. Priority of optimisation should be as followed: CTV > PTV > Bowel Bag > Bladder > Other OAR.

Discussion

In this study we developed a delineation guideline for LRRC based on six cases, delineated by eight radiation oncologists during four multidisciplinary meetings. It was endorsed by a multidisciplinary team of rectal cancer experts responsible for conducting the international multicentre RCT PelvEx II.[28] The most important conclusion is that multidisciplinary evaluation of individual cases is necessary to define target volume. The current guideline provides a first step towards an evidence-based guideline, setting a common and reproducible standard for delineation in all PelvEx II centres. The guideline will be improved based on an ongoing QA programme, multidisciplinary discussions within the PelvEx II trial and follow-up information on developed re-recurrences. Reproducibility and applicability will be investigated within the trial, anticipating a larger case mix.

Inter-observer variation in GTV delineations was large, suggesting that interpretation of diagnostic imaging is challenging in LRRC, especially in tumours located in fibrosis, (case 1.2), and multifocal recurrences (case 1.3). Though current literature suggests high sensitivity and specificity for LRRC detection by FDG-PET and MRI (sensitivity 94–98 % and 80–91 %, specificity 96–98 % and 86–100 % respectively),[29] less evidence is available on determining extent of pelvic disease and on accuracy of delineations. Previous studies show that understaging of disease by radiologists is common, particularly in tumours located in fibrosis or invading in surrounding structures.[30–32] This poses the question how accurate GTV delineation in LRRC currently is. A learning curve in



Fig. 2. Consensus-based GTV and CTV for cases 1.1–2.3 (on the left), with diagnostic MRI (case 1.1, 1.3–2.3) or PET (case 1.2) imaging on the right. 1.1: Recurrence near the pelvic wall. 1.2 (repeated as 2.1): Recurrence located in fibrosis (with black-and-white PET). 1.3: Multifocal recurrence. 2.2: RT-naïve patient with elective CTV delineation as in LARC. 2.3: Lateral recurrence.

Table 4
Recommendations for GTV, CTV and PTV delineation in LRRC.

GTV	General recommendations	• Delineate all macroscopically visible tumour in primary staging Delineate only visibly involved areas of surrounding organs If tumour is located in fibrosis, encompass complete fibrotic area Consult with a dedicated radiologist to determine the extent of the GTV
	Additional recommendations	*In case of induction chemotherapy* • In case of major regression, adjustment towards other non-involved structures is allowed • In case of a complete response, GTV should still be defined (i.e., remaining tumour bed or fibrosis) *In case of tumour located in fibrosis* • Only if tumour and fibrosis can clearly be distinguished, it is optional to reduce the GTV to visible tumour, as long as the fibrosis is completely covered by the CTV
CTV	General recommendations	• Consult with the treating surgeon to determine surgical resection margins at risk for irradical resection and discuss planned type of surgery • CTV = GTV + 1 cm margin • An additional margin of 0.5 cm in dorsolateral region is recommended • Combine multifocal recurrences into one CTV • Use logical anatomical boundaries • Stay 1 cm beyond the most cranial and caudal GTV • Do not adjust CTV towards other organs
	Additional recommendations	*In case of induction chemotherapy* • All pre chemotherapy GTV must be included in the CTV *In RT naive patients* • Additional elective nodal delineation is advised: adhere to national guidelines for LARC • Consider anatomical changes due to prior surgery *In patients undergoing re-irradiation* • No additional elective nodal delineation is advised
PTV	General recommendations	• Apply the PTV margin according to local protocol • Recommended margin between 5 mm and 10 mm

assessment of recurrences is reported in radiologists, in whom exposure to LRRC may be higher compared to radiation oncologists, especially when referred to non-expert radiation oncology clinics for nCRT. [31,33] Therefore, possible future strategies could be demarcation of GTV by expert radiologists, to improve GTV delineations, or delineation of CTV based on known surgical at-risk regions, to ensure adequate CTV coverage, regardless of GTV.

Complete coverage of fibrosis by the GTV is advised, as the risk of irradical resection in fibrotic tissue was deemed high by participating surgeons. This is in line with research performed in primary rectal cancer by Tanaka et al., that concluded that there is a high rate of remaining cancer cells within fibrosis. [34] It is likely that this is similar in LRRC. Moreover, the accuracy of MRI and PET as diagnostic imaging within fibrosis is currently unknown. Therefore, a contouring approach with a reduction of GTV to encompass only PET-positive tumour within fibrosis, whilst covering the remaining fibrosis within the CTV, should remain the exception rather than the rule.

In case 1.3, a multifocal recurrence, not all foci were delineated as GTV by all participants, suggesting that possible tumour miss may occur clinically. Reassuringly, less variation was seen in CTV, as all foci were delineated within one CTV. The rationale behind this is that visible foci of multifocal recurrences may only be the tip of the iceberg and be of a different aetiology than, for example, a lymph node recurrence. Multifocality may be a first manifestation of peritoneal metastatic disease in the pelvis or may be due to seeding or tumour spill. There may also be additional foci present, although not yet visible, which led to the recommendation of combining all foci into one CTV, demarcated by logical anatomical boundaries.

Elective nodal delineation was discussed. For patients undergoing re-irradiation, CTV is based on GTV with an adequate margin to achieve maximal local control. Elective nodal delineation may be beneficial in counteracting microscopic nodal metastases, but as there is no evidence of benefit yet, this is not advised. In addition, at-risk regions for micro metastases or lymph node recurrences cannot be defined yet, as drainage of the pelvis may be substantially altered. Lastly, extensive additional re-irradiation may cause high doses on OARs, increasing toxicity risk.

On the contrary, elective nodal delineation is advised in radiotherapy naïve patients, where the benefit of elective irradiation does seem to outweigh the possible risk of toxicity or exceeding critical OAR doses. An analysis of re-recurrence patterns may provide information needed to define elective target volumes.

No recommendations for OAR constraints were given, as robust data for OAR constraints in reirradiation are lacking. Additionally, OAR are often resected during surgery, especially when the OAR are adjacent to at-risk margins and thus in close proximity to the irradiated target volume. This was recently confirmed by Nordkamp et al. comparing surgical strategies in two large tertiary referral centres for LRRC. [35] Merely 23% of all LRRC patients underwent TME surgery without additional resections and in patients undergoing re-irradiation, that percentage is even lower (18%). [35] Therefore, priority should be placed on adequate target coverage rather than on sparing OAR.

A future priority in treatment planning may be bone-marrow sparing, as data in primary rectal cancer show that CRT can cause hematological toxicity, leading to dose reductions or treatment interruptions that are associated with worse oncological outcomes.[36,37] However, these findings have not yet translated to clinical practice in the form of constraints.

This study is hampered by several limitations. First of all, LRRC is a heterogeneous disease, with varying presentations. Therefore, it is challenging to develop a guideline with wide applicability. Consequently, all delineations of patients treated in the PelvEx II study are prospectively evaluated within a QA programme, in which delineations are reviewed prior to nCRT. Observations made within the PelvEx II trial will be used to improve the guideline where necessary. Second, conclusions are limited due to the small number of cases and observers, especially regarding variation. Inter-observer variation and the potential benefit of a guideline should be studied in larger case series with multiple observers before conclusions can be drawn. Third, there is scarce literature of target volume definition in LRRC and the location of re-

recurrences. Although this emphasizes the importance of this study, there are no prospective data to support the current recommendations. Lastly, the cases presented in this study were selected to represent diverse disease presentation, but had to adhere to PelvEx II inclusion criteria. Therefore, it may not be applicable to irresectable tumours treated with palliative intent.

As described earlier, the most important conclusion is that multidisciplinary evaluation of individual cases was deemed essential. The presence of an expert radiologist proved indispensable to optimize identification of the recurrence. Surgical oncologists were needed to identify areas at particular risk for positive resection margins. In general, it is advised to incorporate surgical at-risk areas into the CTV, to maximize volume reduction and improve chances of achieving a R0 resection, specifically in dorsolateral direction in presacral or lateral pelvic recurrences.

Conclusion

This study provides a first multidisciplinary, consensus-based delineation guideline for LRRC. Analyses of re-recurrences are needed to further understand disease behaviour and recurrence patterns and to optimize delineation guidelines accordingly.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

Special thanks to K. Havenga J. Melenhorst A.G.J. Aalbers E. Angenete, M.L. Lydrup, P. Nilsson, P. Buchwald, J.E. Frödin and H. Iversen for participating in the discussion leading to the consensus guideline.

Funding sources

ZonMw (10070012010003) and Dutch Cancer Society (2020-1/12960) funded the PelvEx II trial.

The funding sources had no role in study design, data collection, data analysis, data interpretation, or writing the paper.

Appendix A. Supplementary material

Supplementary data to this article can be found online at https://doi.org/10.1016/j.radonc.2022.11.008.

References

[1] Tanis PJ, Doeksen A, Van Lanschot JJB. Intentionally curative treatment of locally recurrent rectal cancer: a systematic review. Can J Surg 2013;56:135–44. https://doi.org/10.1503/cjs.025911.

[2] Van Der Meij W, Rombouts AJM, Rutten H, Bremers AJA, De Wilt JHW. Treatment of locally recurrent rectal carcinoma in previously (chemo) irradiated patients: a review. Dis Colon Rectum 2016;59:148–56. https://doi.org/10.1097/DCR.0000000000000547.

[3] van den Brink M, Stiggelbout AM, van den Hout WB, et al. Clinical nature and prognosis of locally recurrent rectal cancer after total mesorectal excision with or without preoperative radiotherapy. J Clin Oncol 2004;22:3958–64. https://doi.org/10.1200/JCO.2004.01.023.

[4] Hagemans JAW, van Rees JM, Alberda WJ, et al. Locally recurrent rectal cancer; long-term outcome of curative surgical and non-surgical treatment of 447 consecutive patients in a tertiary referral centre. Eur J Surg Oncol 2020;46. https://doi.org/10.1016/j.ejso.2019.10.037.

[5] Nielsen M, Rasmussen P, Pedersen B, Hagemann-Madsen R, Lindegaard J, Laurberg S. Early and late outcomes of surgery for locally recurrent rectal cancer: a prospective 10-year study in the total mesorectal excision era. Ann Surg Oncol 2015;22:2677–84. https://doi.org/10.1245/s10434-014-4317-y.

[6] Larsen SG, Wiig JN, Tretli S, Giercksky KE. Surgery and pre-operative irradiation for locally advanced or recurrent rectal cancer in patients over 75 years of age. Colorectal Dis 2006;8:177–85. https://doi.org/10.1111/j.1463-1318.2005.00877.x.

[7] van Gijn W, M Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. *Lancet Oncology*. 2011;12:575-582. doi:10.1016/S1470.

[8] Owens R, Muirhead R. External beam re-irradiation in rectal cancer. Clin Oncol 2018;30:116–23. https://doi.org/10.1016/j.clon.2017.11.009.

[9] Sun DS, Zhang JD, Li L, Dai Y, Yu JM, Shao ZY. Accelerated hyperfractionation field-involved re-irradiation combined with concurrent capecitabine chemotherapy for locally recurrent and irresectable rectal cancer. *British Journal of Radiology*. 2012;85:259-264. doi:10.1259/bjr/28173562.

[10] Lee J, Kim CY, Koom WS, Rim CH. Practical effectiveness of re-irradiation with or without surgery for locoregional recurrence of rectal cancer: a meta-analysis and systematic review. Radiother Oncol 2019;140:10–9. https://doi.org/10.1016/j.radonc.2019.05.021.

[11] Al-Haidari G, Skovlund E, Undseth C, et al. Re-irradiation for recurrent rectal cancer–a single-center experience. Acta Oncol (Madr) 2020;59. https://doi.org/10.1080/0284186X.2020.1725111.

[12] Susko M, Lee J, Salama J, et al. The use of re-irradiation in locally recurrent, non-metastatic rectal cancer. Ann Surg Oncol 2016;23. https://doi.org/10.1245/s10434-016-5250-z.

[13] Guren MG, Undseth C, Rekstad BL, et al. Reirradiation of locally recurrent rectal cancer: a systematic review. Radiother Oncol 2014;113:151–7. https://doi.org/10.1016/j.radonc.2014.11.021.

[14] Youssef FF, Parikh PJ, DeWees TA, et al. Efficacy and toxicity of rectal cancer reirradiation using IMRT for patients who have received prior pelvic radiation therapy. Adv Radiat Oncol 2016;1:94–100. https://doi.org/10.1016/j.adro.2016.02.002.

[15] Beyond TME Collaborative. Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes. In: *The British Journal of Surgery*. Vol 100. ; 2013. doi:10.1002/bjs.9192.

[16] Glynne-Jones R, Wyrwicz L, Tiret E, et al. Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017:28. https://doi.org/10.1093/annonc/mdx224.

[17] Valentini V, Morganti AG, Gambacorta MA, et al. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: a multicentric phase II study. Int J Radiat Oncol Biol Phys 2006;64:1129–39. https://doi.org/10.1016/j.ijrobp.2005.09.017.

[18] Bosman SJ, Holman FA, Nieuwenhuijzen GAP, Martijn H, Creemers GJ, Rutten HJT. Feasibility of reirradiation in the treatment of locally recurrent rectal cancer. Br J Surg 2014;101:1280–9. https://doi.org/10.1002/bjs.9569.

[19] Voogt E, Burger P. Induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer: the PelvEx II study. Eur J Surg Oncol 2021;47:e22–3. https://doi.org/10.1016/j.ejso.2020.11.204.

[20] Voogt ELK, Nordkamp S, Nieuwenhuijzen GAP, et al. Curative treatment of locally recurrent rectal cancer: is induction chemotherapy warranted? Br J Surg 2021;108:e213–4. https://doi.org/10.1093/bjs/znab065.

[21] Enríquez-Navascués JM, Borda N, Lizerazu A, et al. Patterns of local recurrence in rectal cancer after a multidisciplinary approach. World J Gastroenterol 2011;17:1674–84. https://doi.org/10.3748/wjg.v17.i13.1674.

[22] Nijkamp J, De Haas-Kock DFM, Beukema JC, et al. Target volume delineation variation in radiotherapy for early stage rectal cancer in the Netherlands. Radiother Oncol 2012;102. https://doi.org/10.1016/j.radonc.2011.08.011.

[23] Fuller CD, Nijkamp J, Duppen JC, et al. Prospective randomized double-blind pilot study of site-specific consensus atlas implementation for rectal cancer target volume delineation in the cooperative group setting. Int J Radiat Oncol Biol Phys 2011;79. https://doi.org/10.1016/j.ijrobp.2009.11.012.

[24] Voogt ELK, Nordkamp S, Nieuwenhuijzen GAP, et al. Curative treatment of locally recurrent rectal cancer: is induction chemotherapy warranted? Br J Surg 2021;108. https://doi.org/10.1093/bjs/znab065.

[25] Yeo HL, Paty PB. Management of recurrent rectal cancer: practical insights in planning and surgical intervention. J Surg Oncol 2014;109. https://doi.org/10.1002/jso.23457.

[26] Sherer MV, Lin D, Elguindi S, et al. Metrics to evaluate the performance of auto-segmentation for radiation treatment planning: a critical review. Radiother Oncol 2021:160. https://doi.org/10.1016/j.radonc.2021.05.003.

[27] Valentini V, Gambacorta MA, Barbaro B, et al. International consensus guidelines on clinical target volume delineation in rectal cancer. Radiother Oncol 2016;120:195–201. https://doi.org/10.1016/j.radonc.2016.07.017.

[28] Voogt E, Burger P. Induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer: the PelvEx II study. Eur J Surg Oncol 2021;47. https://doi.org/10.1016/j.ejso.2020.11.204.

[29] Ganeshan D, Nougaret S, Korngold E, Rauch GM, Moreno CC. Locally recurrent rectal cancer: what the radiologist should know. Abdom Radiol 2019;44:3709–25. https://doi.org/10.1007/s00261-019-02003-5.

[30] Messiou C, Chalmers AG, Boyle K, Wilson D, Sagar P. Pre-operative MR assessment of recurrent rectal cancer. *British Journal of Radiology*. 2008;81. doi:10.1259/bjr/53300246.

[31] Dresen RC, Kusters M, Daniels-Gooszen AW, et al. Absence of tumor invasion into pelvic structures in locally recurrent rectal cancer: Prediction with preoperative MR imaging. Radiology 2010;256. https://doi.org/10.1148/radiol.10090725.
[32] Brown WE, Koh CE, Badgery-Parker T, Solomon MJ. Validation of MRI and surgical decision making to predict a complete resection in pelvic exenteration for recurrent rectal cancer. In: *Dis Colon Rectum* 2017;Vol 60. https://doi.org/10.1097/DCR.0000000000000766.
[33] Lambregts DMJ, Cappendijk VC, Maas M, Beets GL, Beets-Tan RGH. Value of MRI and diffusion-weighted MRI for the diagnosis of locally recurrent rectal cancer. Eur Radiol 2011;21. https://doi.org/10.1007/s00330-010-2052-8.
[34] Tanaka S, Martling A, Lindholm J, Holm T, Palmer G. Remaining cancer cells within the fibrosis after neo-adjuvant treatment for locally advanced rectal cancer. Eur J Surg Oncol 2015;41. https://doi.org/10.1016/j.ejso.2015.05.019.
[35] Nordkamp S, Voogt ELK, van Zoggel DMGI, et al. Locally recurrent rectal cancer: oncological outcomes with different treatment strategies in two tertiary referral units. Br J Surg 2022;109. https://doi.org/10.1093/bjs/znac083.
[36] Huang W, Dang J, Li Y, Cui HX, Lu WL, Jiang QF. Effect of pelvic bone marrow sparing intensity modulated radiation therapy on acute hematologic toxicity in rectal cancer patients undergoing chemo-radiotherapy. Front Oncol 2021:11. https://doi.org/10.3389/fonc.2021.646211.
[37] Jianyang W, Yuan T, Yuan T, et al. A prospective phase II study of magnetic resonance imaging guided hematopoietical bone marrow–sparing intensity–modulated radiotherapy with concurrent chemotherapy for rectal cancer. Radiol Med (Torino) 2016;121. https://doi.org/10.1007/s11547-015-0605-2.